523 related articles for article (PubMed ID: 18484099)
1. Physicochemical characterization and stability of rifampicin liposome dry powder formulations for inhalation.
Changsan N; Chan HK; Separovic F; Srichana T
J Pharm Sci; 2009 Feb; 98(2):628-39. PubMed ID: 18484099
[TBL] [Abstract][Full Text] [Related]
2. Monitoring safety of liposomes containing rifampicin on respiratory cell lines and in vitro efficacy against Mycobacterium bovis in alveolar macrophages.
Changsan N; Nilkaeo A; Pungrassami P; Srichana T
J Drug Target; 2009 Dec; 17(10):751-62. PubMed ID: 19863196
[TBL] [Abstract][Full Text] [Related]
3. Liposomal dry powders as aerosols for pulmonary delivery of proteins.
Lu D; Hickey AJ
AAPS PharmSciTech; 2005 Dec; 6(4):E641-8. PubMed ID: 16408866
[TBL] [Abstract][Full Text] [Related]
4. Formulation and characterization of lipid-coated tobramycin particles for dry powder inhalation.
Pilcer G; Sebti T; Amighi K
Pharm Res; 2006 May; 23(5):931-40. PubMed ID: 16715383
[TBL] [Abstract][Full Text] [Related]
5. Redispersible liposomal-N-acetylcysteine powder for pulmonary administration: development, in vitro characterization and antioxidant activity.
Ourique AF; Chaves Pdos S; Souto GD; Pohlmann AR; Guterres SS; Beck RC
Eur J Pharm Sci; 2014 Dec; 65():174-82. PubMed ID: 25263567
[TBL] [Abstract][Full Text] [Related]
6. [Stability testing of meloxicam-containing microcomposites for inhalation].
Pomázi A; Ambrus R; Szabóné Révész P
Acta Pharm Hung; 2014; 84(2):55-62. PubMed ID: 25167700
[TBL] [Abstract][Full Text] [Related]
7. Co-encapsulation of isoniazid and rifampicin in liposomes and characterization of liposomes by derivative spectroscopy.
Gürsoy A; Kut E; Ozkirimli S
Int J Pharm; 2004 Mar; 271(1-2):115-23. PubMed ID: 15129978
[TBL] [Abstract][Full Text] [Related]
8. Spray-freeze-drying production of thermally sensitive polymeric nanoparticle aggregates for inhaled drug delivery: effect of freeze-drying adjuvants.
Cheow WS; Ng ML; Kho K; Hadinoto K
Int J Pharm; 2011 Feb; 404(1-2):289-300. PubMed ID: 21093560
[TBL] [Abstract][Full Text] [Related]
9. Heat-Stable Dry Powder Oxytocin Formulations for Delivery by Oral Inhalation.
Fabio K; Curley K; Guarneri J; Adamo B; Laurenzi B; Grant M; Offord R; Kraft K; Leone-Bay A
AAPS PharmSciTech; 2015 Dec; 16(6):1299-306. PubMed ID: 25776985
[TBL] [Abstract][Full Text] [Related]
10. Liposomes for drug delivery to the lungs by nebulization.
Zaru M; Mourtas S; Klepetsanis P; Fadda AM; Antimisiaris SG
Eur J Pharm Biopharm; 2007 Nov; 67(3):655-66. PubMed ID: 17540552
[TBL] [Abstract][Full Text] [Related]
11. Dry powder inhalers: physicochemical and aerosolization properties of several size-fractions of a promising alterative carrier, freeze-dried mannitol.
Kaialy W; Nokhodchi A
Eur J Pharm Sci; 2015 Feb; 68():56-67. PubMed ID: 25497318
[TBL] [Abstract][Full Text] [Related]
12. Physicochemical stability and aerosolization performance of dry powder inhalation system containing ciprofloxacin hydrochloride.
Karimi K; Katona G; Csóka I; Ambrus R
J Pharm Biomed Anal; 2018 Jan; 148():73-79. PubMed ID: 28965047
[TBL] [Abstract][Full Text] [Related]
13. Advanced spray-dried design, physicochemical characterization, and aerosol dispersion performance of vancomycin and clarithromycin multifunctional controlled release particles for targeted respiratory delivery as dry powder inhalation aerosols.
Park CW; Li X; Vogt FG; Hayes D; Zwischenberger JB; Park ES; Mansour HM
Int J Pharm; 2013 Oct; 455(1-2):374-92. PubMed ID: 23820131
[TBL] [Abstract][Full Text] [Related]
14. Spray-dried carrier-free dry powder tobramycin formulations with improved dispersion properties.
Pilcer G; Vanderbist F; Amighi K
J Pharm Sci; 2009 Apr; 98(4):1463-75. PubMed ID: 18752304
[TBL] [Abstract][Full Text] [Related]
15. Overcoming dose limitations using the orbital(®) multi-breath dry powder inhaler.
Young PM; Crapper J; Philips G; Sharma K; Chan HK; Traini D
J Aerosol Med Pulm Drug Deliv; 2014 Apr; 27(2):138-47. PubMed ID: 24004178
[TBL] [Abstract][Full Text] [Related]
16. Co-spray drying of hygroscopic kanamycin with the hydrophobic drug rifampicin to improve the aerosolization of kanamycin powder for treating respiratory infections.
Momin MAM; Tucker IG; Doyle CS; Denman JA; Sinha S; Das SC
Int J Pharm; 2018 Apr; 541(1-2):26-36. PubMed ID: 29458207
[TBL] [Abstract][Full Text] [Related]
17. Physicochemical characterization and skin permeation of liposome formulations containing clindamycin phosphate.
Shanmugam S; Song CK; Nagayya-Sriraman S; Baskaran R; Yong CS; Choi HG; Kim DD; Woo JS; Yoo BK
Arch Pharm Res; 2009 Jul; 32(7):1067-75. PubMed ID: 19641889
[TBL] [Abstract][Full Text] [Related]
18. Powder properties and their influence on dry powder inhaler delivery of an antitubercular drug.
Sethuraman VV; Hickey AJ
AAPS PharmSciTech; 2002; 3(4):E28. PubMed ID: 12916922
[TBL] [Abstract][Full Text] [Related]
19. Spray freeze drying to produce a stable Delta(9)-tetrahydrocannabinol containing inulin-based solid dispersion powder suitable for inhalation.
van Drooge DJ; Hinrichs WL; Dickhoff BH; Elli MN; Visser MR; Zijlstra GS; Frijlink HW
Eur J Pharm Sci; 2005 Oct; 26(2):231-40. PubMed ID: 16084699
[TBL] [Abstract][Full Text] [Related]
20. Physicochemical characterization and aerosol dispersion performance of organic solution advanced spray-dried microparticulate/nanoparticulate antibiotic dry powders of tobramycin and azithromycin for pulmonary inhalation aerosol delivery.
Li X; Vogt FG; Hayes D; Mansour HM
Eur J Pharm Sci; 2014 Feb; 52():191-205. PubMed ID: 24215736
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
